AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RLAY

Bergstrom Donald A sold $42K of RLAY

Bergstrom Donald A (President, R&D) sold 2,252 shares of Relay Therapeutics, Inc. (RLAY) at $18.62 on 2026-10-28.

Original reporting
SEC EDGAR · Bergstrom Donald A
Published Oct 30, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RLAY
Bearish
medium confidence
Mentioned
$RLAY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLAYBearishLow
01

Why it matters

Provides fresh data on insider holdings.

02

Market read

Small insider sale with limited market impact.

03

What to watch

No 10b5‑1 plan; could be routine diversification.

Relevance 3/10Novelty 3/10Timing: filing date today

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

$RLAYBearishMedium confidence
Context

President of R&D sold 2,252 shares for $41.9K, reducing his stake to 396,878 shares.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

Small insider sale by a senior executive, no pre‑arranged plan, could be perceived as a mild bearish signal.

Market effects

Sector

Minimal impact on biotech sector.

Regional

None.

Global

Low.

Counterpoint

What could challenge this read

The sale may simply be personal liquidity and not indicative of company outlook.

Key entities

  • Company
    Relay Therapeutics, Inc.

    Biotech firm listed on NASDAQ.

  • Person
    Donald A. Bergstrom

    President, R&D at Relay Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RLAY insider trading history →

Related articles

$RLAYHigh

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies t

SEC EDGAR 8-K
$RLAYMed

Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay

SEC EDGAR 8-K
$RLAYLowAI 8/10

Relay Therapeutics Shares Jump 18%

Relay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.

rttnews.com